Monopar Therapeutics MNPR 深 滬
已收盤 02-06 16:00:00 美东时间
57.75
+0.870
+1.53%
華盛通- 最 高61.20
- 今 開57.92
- 成交量 32.67万股
- 最 低 57.45
- 昨 收 56.88
- 總市值 3.86亿
- 52周最高 105.00
- 市盈率 靜 --
- 換手率 4.89%
- 52周最低 26.055
- 委 比 29.45%
- 總股本 668.26万
- 歷史最高 240.00
- 量 比 1.11
- 振 幅 6.59%
- 歷史最低 1.3695
- 每 手 1
- 風險率 20.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $115
Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $115.
01-09 21:02
The Year-End 2025 Biotech Rally And What It Means For 2026
Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a ...
2025-12-31 23:54
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses of $(0.37) per share
2025-11-13 21:06
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. presented new data from the Phase 2 ALXN1840-WD-204 study at the AASLD Liver Meeting 2025, showing that ALXN1840 (tiomolybdate choline) improved copper balance in Wilson disease patients through increased fecal copper excretion. Results from 8 patients demonstrated significant improvement during the 15 mg once-daily dosing period and throughout the entire treatment duration. Additional supporting data will also be presen...
2025-11-09 14:00
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. announced that its Phase 2 ALXN1840-WD-204 copper balance study abstract has been selected for oral presentation at the AASLD Liver Meeting 2025. The session, titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," will take place on November 9, 2025, at 9:00-9:15 am EST. For more details, visit the conference website or www.monopartx.com.
2025-10-15 12:00
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
2025-10-14 09:56
